Background
Founded on January 19, 2018, Jiyi is a biotech enterprise focusing on the field of cancer treatment. The collection company has set up a number of cancer product management lines. Anti-PD-1 and anti-PD-L1 phenotypes are the cornerstones of immunotherapy and the backbone of the cluster line. The market submitted the anti-PD-1 phenotype HX008 (pucotenlimab) NDA for the treatment of MSI-H/dMMR to the State Supervision Bureau in October 2021. We are also committed to developing ADC and oncolytic virus products. According to Frost Sullivan's data, according to the statistics of the number of ADC hosts in the bed section, the centralized ADC client management line is in the leading position in the mainland.
Summary
The industry is developing rapidly: in recent years, the global and inland biological market has grown rapidly, and it is expected that it will grow in the near future. Driven by the increase in market demand, the market regulation model of geobiology in 2019 is 3120 billion yuan, and it is expected to reach 7125 yuan and 13029 billion yuan respectively by 2024 and 2030, respectively. The compound annual growth rate from 2019 to 2024 is 18.0%. The compound annual growth rate from 2024 to 2030 is 10.6%. The global market regulation model of biochemistry is 2864 billion US dollars in 2019, and is expected to reach 4567 billion US dollars in 2024 and 7680 billion US dollars in 2030, respectively. The complex annual growth rate from 2019 to 2024 is 9.8%.
The number of new cancer cases worldwide and inland has been on the rise: in 2020, there were 193 million new cancer cases worldwide, and it is expected to reach 2.16 million in 2025 and 240,000 in 2030. The annual growth rate from 2020 to 2025 is 2.4%. The annual growth rate from 2025 to 2030 is 2.1%. In 2020, there were 46 million new cancer cases in the mainland, expected to reach 52 million in 2025 and 58 million in 2030, with a complex annual growth rate of 2.6% from 2020 to 2025 and 2.3% from 2025 to 2030.
It has four core products: as of the last practicable date, there are (I) eight bed segments; (ii) three bed segments; and (iii) three bed segments in the product line. Among the eight bed segments of the collection, five were targeted, three were immunized, and one of these three was immune checkpoint and oncolytic virus. As of the last practicable date, 28 projects have been launched, three of which have entered a critical phase and are being carried out in the United States.